Nasus Pharma Announces Pricing of $10 Million Initial Public Offering

Core Viewpoint - Nasus Pharma Ltd. has successfully priced its initial public offering (IPO) of 1,250,000 ordinary shares at $8.00 per share, aiming for gross proceeds of $10 million before expenses [1][4]. Group 1: IPO Details - The IPO consists of 1,250,000 ordinary shares priced at $8.00 each, targeting total gross proceeds of $10 million [1]. - An additional option for underwriters allows them to purchase up to 187,500 ordinary shares within 45 days to cover over-allotments [1]. - The shares are approved for listing on NYSE American under the ticker symbol "NSRX," with trading expected to commence on August 13, 2025 [3]. Group 2: Use of Proceeds - The net proceeds from the IPO will primarily fund the development of the intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies [2]. - Remaining funds will be allocated for general corporate purposes, including working capital and capital expenditures [2]. Group 3: Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal products for emergency medical conditions [6]. - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine designed as a needle-free alternative for anaphylaxis treatment [6]. - The proprietary powder-based intranasal (PBI) technology aims for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [6].